{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:28:02Z","timestamp":1790836082665,"version":"4.1.0"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:p>Gray-zone lymphoma (GZL) with features intermediate between classic Hodgkin lymphoma (cHL) and large B-cell lymphoma (LBCL) was introduced as a provisional entity into the World Health Organization classification in 2008. However, as diagnostic criteria are imprecise, reliable identification of GZL cases remains challenging. Here, we describe the histopathologic features of 139 GZL cases from a retrospective Lymphoma Study Association (LYSA) study with the goal to improve classification accuracy. Inclusion criteria were based on literature review and an expert consensus opinion of the LYSA hematopathologist panel. We observed 86 cases with a morphology more closely related to cHL, but with an LBCL immunophenotype based on strong and homogenous B-cell marker expression (CD20 and\/or CD79a, OCT2, BOB1, PAX5) on all tumor cells (cHL-like GZL). Fifty-three cases were morphologically more closely related to LBCL but harbored a cHL immunophenotype (LBCL-like GZL). Importantly, we observed a continuous morphologic and immunophenotypic spectrum within these 2 GZL categories. The majority of cases presented genetic immune escape features with <jats:italic toggle=\"yes\">CD274\/PDCD1LG2<\/jats:italic> and\/or <jats:italic toggle=\"yes\">CIITA<\/jats:italic> structural variants by fluorescence in situ hybridization. Patients without mediastinal involvement at diagnosis (17%) were older than those with mediastinal tumors (median: 56 vs. 39\u2009y). Cases associated with Epstein-Barr virus (24%) presented with similar patient characteristics and outcome as Epstein-Barr virus negative cases. In summary, we provide refined diagnostic criteria that contribute to a more precise pathologic and clinical characterization of GZL within a broad spectrum from cHL-like to LBCL-like disease.<\/jats:p>","DOI":"10.1097\/pas.0000000000001198","type":"journal-article","created":{"date-parts":[[2018,12,12]],"date-time":"2018-12-12T00:06:27Z","timestamp":1544573187000},"page":"341-351","source":"Crossref","is-referenced-by-count":76,"title":["Gray-zone Lymphoma Between cHL and Large B-Cell Lymphoma"],"prefix":"10.1097","volume":"43","author":[{"given":"Cl\u00e9mentine","family":"Sarkozy","sequence":"first","affiliation":[{"name":"Hospital, Hematology Department, Hospices Civils Lyon, Lyon-Sud"},{"name":"INSERM1052, CNRS 5286, Lyon-Sud Charles M\u00e9rieux Lyon-1 Faculty, Claude Bernard University"},{"name":"Department for Lymphoid Cancer Research, Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Copie-Bergman","sequence":"additional","affiliation":[{"name":"Pathology Department, Henri Mondor-Albert Chennevier Hospital, APHP, Paris Est-Cr\u00e9teil (UPEC) University Faculty, UMR-S 955, INSERM, Cr\u00e9teil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Damotte","sequence":"additional","affiliation":[{"name":"Pathology Department, Groupe Hospitalier Cochin, APHP, Paris Descartes University-Sorbonne Paris Cit\u00e9"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Ben-Neriah","sequence":"additional","affiliation":[{"name":"Department for Lymphoid Cancer Research, Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Burroni","sequence":"additional","affiliation":[{"name":"Pathology Department, Groupe Hospitalier Cochin, APHP, Paris Descartes University-Sorbonne Paris Cit\u00e9"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9rome","family":"Cornillon","sequence":"additional","affiliation":[{"name":"Hematology Department, Lucien Neuwirth Cancer Institut, St Priest en Jarez"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Lemal","sequence":"additional","affiliation":[{"name":"Hematology Department, CHU Clermont-Ferrand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Golfier","sequence":"additional","affiliation":[{"name":"Hematology Department, CHU Dijon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Fabiani","sequence":"additional","affiliation":[{"name":"Pathology Department, H\u00f4pital Saint Antoine, APHP"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Chassagne-Cl\u00e9ment","sequence":"additional","affiliation":[{"name":"Pathology Department, Centre L\u00e9on B\u00e9rard, Lyon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Parrens","sequence":"additional","affiliation":[{"name":"Pathology Department, CHU de Bordeaux"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Herbaux","sequence":"additional","affiliation":[{"name":"Hematology Department, CHRU de Lille"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Xerri","sequence":"additional","affiliation":[{"name":"Cancer Research Center of Marseille, Inserm U1068\/CNRS U7258, Institut Paoli-Calmettes, Aix Marseille Universit\u00e9, Marseille"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Bossard","sequence":"additional","affiliation":[{"name":"Pathology Department, CHU de Nantes"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Laurent","sequence":"additional","affiliation":[{"name":"Pathology Department, Institut Universitaire du Cancer-Oncopole, CHU Toulouse, INSERM, U.1037, Centre de recherche en canc\u00e9rologie de Toukouse-Purpan, Toulouse"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgane","family":"Cheminant","sequence":"additional","affiliation":[{"name":"Clinical Hematology, Necker-Enfants Malades University Hospital, AP-HP, Paris Descartes University-Sorbonne Paris Cit\u00e9, Paris"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Cartron","sequence":"additional","affiliation":[{"name":"Hematology Department, CHU Montpellier"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Cabecadas","sequence":"additional","affiliation":[{"name":"Departamento de Diagn\u00f3stico Laboratorial, Instituto Portugu\u00eas de Oncologia de Lisboa\u2013IPO, Lisbon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Molina","sequence":"additional","affiliation":[{"name":"Necker Enfants Malades Hospital, Universit\u00e9 Paris Descartes, APHP"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[{"name":"Hospital, Hematology Department, Hospices Civils Lyon, Lyon-Sud"},{"name":"INSERM1052, CNRS 5286, Lyon-Sud Charles M\u00e9rieux Lyon-1 Faculty, Claude Bernard University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Steidl","sequence":"additional","affiliation":[{"name":"Department for Lymphoid Cancer Research, Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Ghesqui\u00e8res","sequence":"additional","affiliation":[{"name":"Hospital, Hematology Department, Hospices Civils Lyon, Lyon-Sud"},{"name":"INSERM1052, CNRS 5286, Lyon-Sud Charles M\u00e9rieux Lyon-1 Faculty, Claude Bernard University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Mottok","sequence":"additional","affiliation":[{"name":"Department for Lymphoid Cancer Research, Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"},{"name":"Institute of Human Genetics, Ulm University and Ulm University Medical Center, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Traverse-Glehen","sequence":"additional","affiliation":[{"name":"INSERM1052, CNRS 5286, Lyon-Sud Charles M\u00e9rieux Lyon-1 Faculty, Claude Bernard University"},{"name":"Pathology Department, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud69495 Pierre B\u00e9nite Cedex"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20230922","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"R3-20230922","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1080\/10428190310001623775","article-title":"Gene expression profiling of diffuse large B-cell lymphoma","volume":"44","author":"Rosenwald","year":"2003","journal-title":"Leuk Lymph"},{"key":"R4-20230922","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1056\/NEJMra020067","article-title":"Molecular diagnosis of the hematologic cancers","volume":"348","author":"Staudt","year":"2003","journal-title":"N Engl J Med"},{"key":"R5-20230922","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1182\/blood-2015-01-623777","article-title":"A roadmap for discovery and translation in lymphoma","volume":"125","author":"Weinstock","year":"2015","journal-title":"Blood"},{"key":"R6-20230922","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/annonc\/9.suppl_5.S31","article-title":"Workshop report on Hodgkin\u2019s disease and related diseases (\u201cgrey zone\u201d lymphoma)","volume":"9","author":"Rudiger","year":"1998","journal-title":"Ann Oncol"},{"key":"R7-20230922","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1097\/01.pas.0000180856.74572.73","article-title":"Mediastinal gray zone lymphoma: the missing link between classic Hodgkin\u2019s lymphoma and mediastinal large B-cell lymphoma","volume":"29","author":"Traverse-Glehen","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"R8-20230922","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2559.2005.02175.x","article-title":"Large B-cell lymphoma with Hodgkin\u2019s features","volume":"47","author":"Garcia","year":"2005","journal-title":"Histopathology"},{"key":"R9-20230922","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3324\/haematol.2010.030809","article-title":"Clinical, pathological and genetic features of primary mediastinal large B-cell lymphomas and mediastinal gray zone lymphomas in children","volume":"96","author":"Oschlies","year":"2011","journal-title":"Haematologica"},{"key":"R10-20230922","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s12308-009-0053-9","article-title":"Gray zones around diffuse large B cell lymphoma. Conclusions based on the workshop of the XIV meeting of the European Association for Hematopathology and the Society of Hematopathology in Bordeaux, France","volume":"2","author":"Quintanilla-Martinez","year":"2009","journal-title":"J Hematopathol"},{"key":"R11-20230922","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/PAI.0000000000000236","article-title":"Distinguishing classical Hodgkin lymphoma, gray zone lymphoma, and large B-cell lymphoma: a proposed scoring system","volume":"24","author":"O\u2019Malley","year":"2016","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"R12-20230922","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1038\/modpathol.2011.116","article-title":"Gray zone lymphoma: chromosomal aberrations with immunophenotypic and clinical correlations","volume":"24","author":"Eberle","year":"2011","journal-title":"Mod Pathol"},{"key":"R13-20230922","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3960\/jslrt.50.143","article-title":"Two cases of mediastinal gray zone lymphoma","volume":"50","author":"Minami","year":"2010","journal-title":"J Clin Exp Hematop"},{"key":"R14-20230922","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/modpathol.2011.200","article-title":"The spectrum of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma: a description of 10 cases","volume":"25","author":"Gualco","year":"2012","journal-title":"Mod Pathol"},{"key":"R15-20230922","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1182\/bloodadvances.2017009472","article-title":"Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL","volume":"1","author":"Pilichowska","year":"2017","journal-title":"Blood Adv"},{"key":"R16-20230922","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/ajh.24082","article-title":"Gray zone lymphoma with features intermediate between classical hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort","volume":"90","author":"Evens","year":"2015","journal-title":"Am J Hematol"},{"key":"R17-20230922","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1200\/JCO.2016.71.2083","article-title":"Impact of expert pathologic review of lymphoma diagnosis: study of patients from the French Lymphopath Network","volume":"35","author":"Laurent","year":"2017","journal-title":"J Clin Oncol"},{"key":"R18-20230922","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3324\/haematol.2016.152256","article-title":"Mediastinal gray zone lymphoma: clinico-pathological characteristics and outcomes of 99 patients from the Lymphoma Study Association","volume":"102","author":"Sarkozy","year":"2017","journal-title":"Haematologica"},{"key":"R19-20230922","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1182\/blood.V94.10.3567.422k06_3567_3575","article-title":"The MAL gene is expressed in primary mediastinal large B-cell lymphoma","volume":"94","author":"Copie-Bergman","year":"1999","journal-title":"Blood"},{"key":"R20-20230922","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nature09754","article-title":"MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers","volume":"471","author":"Steidl","year":"2011","journal-title":"Nature"},{"key":"R21-20230922","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1182\/blood-2009-12-257345","article-title":"Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome","volume":"116","author":"Steidl","year":"2010","journal-title":"Blood"},{"key":"R22-20230922","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1097\/01.MP.0000093627.51090.3F","article-title":"Expression of B-cell markers in classical Hodgkin lymphoma: a tissue microarray analysis of 330 cases","volume":"16","author":"Tzankov","year":"2003","journal-title":"Mod Pathol"},{"key":"R23-20230922","doi-asserted-by":"crossref","first-page":"e6341","DOI":"10.1371\/journal.pone.0006341","article-title":"Prognostic significance of new immunohistochemical markers in refractory classical Hodgkin lymphoma: a study of 59 cases","volume":"4","author":"Canioni","year":"2009","journal-title":"PLoS ONE"},{"key":"R24-20230922","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/bjh.13085","article-title":"CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia","volume":"167","author":"Slack","year":"2014","journal-title":"Br J Haematol"},{"key":"R25-20230922","doi-asserted-by":"crossref","first-page":"e0126615","DOI":"10.1371\/journal.pone.0126615","article-title":"The expression of CD30 based on immunohistochemistry predicts inferior outcome in patients with diffuse large B-cell lymphoma","volume":"10","author":"Hao","year":"2015","journal-title":"PLoS One"},{"key":"R26-20230922","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1586\/17474086.2015.991388","article-title":"Immunoarchitectural patterns in nodular lymphocyte predominant Hodgkin lymphoma: pathologic and clinical implications","volume":"8","author":"Gloghini","year":"2015","journal-title":"Expert Rev Hematol"},{"key":"R27-20230922","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood-2015-02-630632","article-title":"EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment","volume":"126","author":"Nicolae","year":"2015","journal-title":"Blood"},{"key":"R28-20230922","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/his.13100","article-title":"Grey zone lymphoma with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma: a clinicopathological study of 14 Epstein-Barr virus-positive cases","volume":"70","author":"Elsayed","year":"2017","journal-title":"Histopathology"},{"key":"R29-20230922","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/j.celrep.2015.10.008","article-title":"Genomic alterations in CIITA are frequent in primary mediastinal large B cell lymphoma and are associated with diminished MHC class II expression","volume":"13","author":"Mottok","year":"2015","journal-title":"Cell Rep"},{"key":"R30-20230922","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2013-10-535443","article-title":"Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma","volume":"123","author":"Twa","year":"2014","journal-title":"Blood"},{"key":"R31-20230922","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol"},{"key":"R32-20230922","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1182\/blood-2017-09-808907","article-title":"Somatic IL4R mutations in primary mediastinal large B-cell lymphoma lead to constitutive JAK-STAT signaling activation","volume":"131","author":"Vigano","year":"2018","journal-title":"Blood"},{"key":"R33-20230922","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"R34-20230922","doi-asserted-by":"crossref","first-page":"44960","DOI":"10.18632\/oncotarget.16680","article-title":"Mechanisms of PD-1\/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies","volume":"8","author":"Gravelle","year":"2017","journal-title":"Oncotarget"},{"key":"R35-20230922","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"R36-20230922","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1182\/blood-2014-03-564906","article-title":"A prospective study of mediastinal gray-zone lymphoma","volume":"124","author":"Wilson","year":"2014","journal-title":"Blood"},{"key":"R37-20230922","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","article-title":"Lymphoma\/leukemia molecular profiling P: stromal gene signatures in large-B-cell lymphomas","volume":"359","author":"Lenz","year":"2008","journal-title":"N Engl J Med"},{"key":"R38-20230922","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJMc1704767","article-title":"PD-1 blockade in mediastinal gray-zone lymphoma","volume":"377","author":"Melani","year":"2017","journal-title":"N Engl J Med"},{"key":"R39-20230922","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1634\/theoncologist.2017-0004","article-title":"FDA approval summary: nivolumab for the treatment of relapsed or progressive classical Hodgkin lymphoma","volume":"22","author":"Kasamon","year":"2017","journal-title":"Oncologist"},{"key":"R40-20230922","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1182\/blood-2016-12-758383","article-title":"Safety and tolerability of pembrolizumab in patients with relapsed\/refractory primary mediastinal large B-cell lymphoma","volume":"130","author":"Zinzani","year":"2017","journal-title":"Blood"},{"key":"R41-20230922","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s40265-017-0705-5","article-title":"Brentuximab vedotin: a review in CD30-positive Hodgkin lymphoma","volume":"77","author":"Scott","year":"2017","journal-title":"Drugs"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000478-201903000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T22:45:33Z","timestamp":1695422733000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000478-201903000-00006"}},"subtitle":["A Histopathologic Series From the LYSA"],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000001198","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]}}}